499 related articles for article (PubMed ID: 27748747)
1. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
[TBL] [Abstract][Full Text] [Related]
2. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470.
Gervaz P; Scholl B; Padrun V; Gillet M
Liver; 2000 Apr; 20(2):108-13. PubMed ID: 10847478
[TBL] [Abstract][Full Text] [Related]
4. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
5. Vessel co-option and resistance to anti-angiogenic therapy.
Kuczynski EA; Reynolds AR
Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
[TBL] [Abstract][Full Text] [Related]
6. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
7. Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies.
Lazaris A; Amri A; Petrillo SK; Zoroquiain P; Ibrahim N; Salman A; Gao ZH; Vermeulen PB; Metrakos P
J Pathol Clin Res; 2018 Jul; 4(3):184-192. PubMed ID: 29654716
[TBL] [Abstract][Full Text] [Related]
8. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
Umehara M; Umehara Y; Takahashi K; Murata A; Nishikawa S; Tokura T; Matsuzaka M; Tanaka R; Morita T
Anticancer Res; 2016 Apr; 36(4):1949-54. PubMed ID: 27069185
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis targeting in gastro-intestinal cancers].
Meric JB
Bull Cancer; 2007; 94(7 Suppl):F207-15. PubMed ID: 17964998
[TBL] [Abstract][Full Text] [Related]
11. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
12. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Kuczynski EA; Kerbel RS
Chin J Cancer; 2016 Nov; 35(1):97. PubMed ID: 27887628
[TBL] [Abstract][Full Text] [Related]
13. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
15. Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab.
Weisshardt P; Trarbach T; Dürig J; Paul A; Reis H; Tilki D; Miroschnik I; Ergün S; Klein D
Histochem Cell Biol; 2012 Mar; 137(3):391-401. PubMed ID: 22193946
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis.
Finkelmeier F; You SJ; Waidmann O; Wolff R; Zeuzem S; Bähr O; Trojan J
J Gastrointest Cancer; 2016 Mar; 47(1):82-8. PubMed ID: 26714801
[TBL] [Abstract][Full Text] [Related]
17. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?
Giampieri R; Caporale M; Pietrantonio F; De Braud F; Negri FV; Giuliani F; Pusceddu V; Demurtas L; Restivo A; Fontanella C; Aprile G; Cascinu S; Scartozzi M
Crit Rev Oncol Hematol; 2016 Apr; 100():99-106. PubMed ID: 26907512
[TBL] [Abstract][Full Text] [Related]
18. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
19. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases.
Maru DM; Kopetz S; Boonsirikamchai P; Agarwal A; Chun YS; Wang H; Abdalla EK; Kaur H; Charnsangavej C; Vauthey JN; Loyer EM
Am J Surg Pathol; 2010 Sep; 34(9):1287-94. PubMed ID: 20697255
[TBL] [Abstract][Full Text] [Related]
20. An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab.
Sclafani F; Rimassa L; Colombo P; Destro A; Stinco S; Lutman FR; Carnaghi C; Beretta G; Zanello A; Roncalli M; Giordano L; Santoro A
Int J Biol Markers; 2015 Feb; 30(1):e73-80. PubMed ID: 24980447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
